Abstract
A basic element in the protection of human subjects in clinical trials is the requirement for informed consent. Informed consent, and the particular minimum information that must be provided to subjects, is regulated in the United States by the FDA and by regulatory authorities in other countries. The informed consent document (ICD) provides a basis for assuring that appropriate information is provided to potential subjects. This paper discusses problems that may be encountered in two specific aspects of the ICD, namely, readability and adequacy of content to comply with regulations. Specific issues related to trials involving long-term implantable medical devices are considered. Suggestions for improving informed consent in such trials are provided.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
